focu shift post-earn receiv multipl
inquiri expect pnh readout risk-reward
go event think non-inferior close certain strong trend
highli probabl superior ldh normal co-primari
endpoint look like pleas see
packag preview expect data readout outlin
possibl outcom scenario also highlight dynam model
use test assumpt alxn complement franchis
highlight post-earn call manag continu
view financi guidanc conserv see soliri gmg sale
pick year along trial headwind becom
tailwind support brighter outlook also clarifi question
receiv investor relat case meningococc
infect among subject manag emphas
believ rate infect consist note
soliri dmc express concern around
infect see strong rational present differenti risk
profil relat meningococc infect kol spoken
appear concern front
updat model updat model result
guidanc lower opex increas ep
tp thesi unchang share
trade ep see attract entri point ahead
view high-prob pnh readout
valuat reiter outperform rate price
valuat base blend dcf project risk includ clinic trial
failur increas competit novel agent biosimilar
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
alexion biotechnolog compani focus research
develop commerci therapeut rare diseas
alexion drug soliri use treat patient complement
mediat disord product includ strensiq
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
establish superior efficaci soliri pnh
trial posit nmo data increas pipelin valu
fail establish non-inferior efficaci soliri failur
nmo decreas pipelin valu
 close
million except ep
incom tax non-gaap
compani mention price
